176 related articles for article (PubMed ID: 24858311)
1. Identification of DW532 as a novel anti-tumor agent targeting both kinases and tubulin.
Peng T; Wu JR; Tong LJ; Li MY; Chen F; Leng YX; Qu R; Han K; Su Y; Chen Y; Duan WH; Xie H; Ding J
Acta Pharmacol Sin; 2014 Jul; 35(7):916-28. PubMed ID: 24858311
[TBL] [Abstract][Full Text] [Related]
2. A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton.
Zhang J; Zhou J; Ren X; Diao Y; Li H; Jiang H; Ding K; Pei D
Invest New Drugs; 2012 Apr; 30(2):490-507. PubMed ID: 21080210
[TBL] [Abstract][Full Text] [Related]
3. DCLAK11, a multi-tyrosine kinase inhibitor, exhibits potent antitumor and antiangiogenic activity in vitro.
Guo XB; Chen XJ; Tong LJ; Peng X; Huang M; Liu HC; Liu H; Ding J
Acta Pharmacol Sin; 2015 Oct; 36(10):1266-76. PubMed ID: 26027659
[TBL] [Abstract][Full Text] [Related]
4. A novel sulfonamide agent, MPSP-001, exhibits potent activity against human cancer cells in vitro through disruption of microtubule.
Liu ZL; Tian W; Wang Y; Kuang S; Luo XM; Yu Q
Acta Pharmacol Sin; 2012 Feb; 33(2):261-70. PubMed ID: 22301862
[TBL] [Abstract][Full Text] [Related]
5. A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancer.
Pan Y; Zheng M; Zhong L; Yang J; Zhou S; Qin Y; Xiang R; Chen Y; Yang SY
Mol Cancer Ther; 2015 Feb; 14(2):407-18. PubMed ID: 25519702
[TBL] [Abstract][Full Text] [Related]
6. New antiproliferative 3-substituted oxindoles inhibiting EGFR/VEGFR-2 and tubulin polymerization.
Ezelarab HAA; Ali TFS; Abbas SH; Sayed AM; Beshr EAM; Hassan HA
Mol Divers; 2024 Apr; 28(2):563-580. PubMed ID: 36790582
[TBL] [Abstract][Full Text] [Related]
7. C118P, a novel microtubule inhibitor with anti-angiogenic and vascular disrupting activities, exerts anti-tumor effects against hepatocellular carcinoma.
Yang M; Su Y; Wang Z; Du D; Wei S; Liao Z; Zhang Q; Zhao L; Zhang X; Han L; Jiang J; Zhan M; Sun L; Yuan S; Zhou Z
Biochem Pharmacol; 2021 Aug; 190():114641. PubMed ID: 34077738
[TBL] [Abstract][Full Text] [Related]
8. Pyrazoline derivatives as tubulin polymerization inhibitors with one hit for Vascular Endothelial Growth Factor Receptor 2 inhibition.
Yang B; Zhou J; Wang F; Hu XW; Shi Y
Bioorg Chem; 2021 Sep; 114():105134. PubMed ID: 34246970
[TBL] [Abstract][Full Text] [Related]
9. DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo.
Li MY; Lv YC; Tong LJ; Peng T; Qu R; Zhang T; Sun YM; Chen Y; Wei LX; Geng MY; Duan WH; Xie H; Ding J
Acta Pharmacol Sin; 2016 Mar; 37(3):398-407. PubMed ID: 26806300
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of novel benzo[c]acridine-diones as potential anticancer agents and tubulin polymerization inhibitors.
Behbahani FS; Tabeshpour J; Mirzaei S; Golmakaniyoon S; Tayarani-Najaran Z; Ghasemi A; Ghodsi R
Arch Pharm (Weinheim); 2019 Jun; 352(6):e1800307. PubMed ID: 31012156
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of benzoylacrylic acid shikonin ester derivatives as irreversible dual inhibitors of tubulin and EGFR.
Sun WX; Han HW; Yang MK; Wen ZL; Wang YS; Fu JY; Lu YT; Wang MY; Bao JX; Lu GH; Qi JL; Wang XM; Lin HY; Yang YH
Bioorg Med Chem; 2019 Dec; 27(23):115153. PubMed ID: 31648877
[TBL] [Abstract][Full Text] [Related]
12. Anti-angiogenic and vascular disrupting effects of C9, a new microtubule-depolymerizing agent.
Ren X; Dai M; Lin LP; Li PK; Ding J
Br J Pharmacol; 2009 Apr; 156(8):1228-38. PubMed ID: 19302593
[TBL] [Abstract][Full Text] [Related]
13. Novel Benzo[B]Furans with Anti-Microtubule Activity Upregulate Expression of Apoptotic Genes and Arrest Leukemia Cells in G2/M Phase.
Królewska-Golińska K; Cieślak MJ; Sobczak M; Dolot R; Radzikowska-Cieciura E; Napiórkowska M; Wybrańska I; Nawrot B
Anticancer Agents Med Chem; 2019; 19(3):375-388. PubMed ID: 30465514
[TBL] [Abstract][Full Text] [Related]
14. Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.
Wang D; Tang F; Wang S; Jiang Z; Zhang L
Cancer Chemother Pharmacol; 2012 Jan; 69(1):173-83. PubMed ID: 21638122
[TBL] [Abstract][Full Text] [Related]
15. Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via VEGFR-2 signaling pathway in breast cancer.
Wang N; Wang ZY; Mo SL; Loo TY; Wang DM; Luo HB; Yang DP; Chen YL; Shen JG; Chen JP
Breast Cancer Res Treat; 2012 Aug; 134(3):943-55. PubMed ID: 22350787
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor activity and mechanisms of a novel vascular disrupting agent, (Z)-3,4',5-trimethoxylstilbene-3'-O-phosphate disodium (M410).
Cai YC; Zou Y; Ye YL; Sun HY; Su QG; Wang ZX; Zeng ZL; Xian LJ
Invest New Drugs; 2011 Apr; 29(2):300-11. PubMed ID: 20012336
[TBL] [Abstract][Full Text] [Related]
17. Deacetylisovaltratum disrupts microtubule dynamics and causes G
Zhang D; Zhang B; Zhou LX; Zhao J; Yan YY; Li YL; Zeng JM; Wang LL; Yang B; Lin NM
Acta Pharmacol Sin; 2016 Dec; 37(12):1597-1605. PubMed ID: 27665846
[TBL] [Abstract][Full Text] [Related]
18. A novel 2-aminobenzimidazole-based compound Jzu 17 exhibits anti-angiogenesis effects by targeting VEGFR-2 signalling.
Lien JC; Chung CL; Huang TF; Chang TC; Chen KC; Gao GY; Hsu MJ; Huang SW
Br J Pharmacol; 2019 Oct; 176(20):4034-4049. PubMed ID: 31368127
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor angiogenesis effect of a new compound: B-9-3 through interference with VEGFR2 signaling.
Ma Q; Chen W; Chen W
Tumour Biol; 2016 May; 37(5):6107-16. PubMed ID: 26611645
[TBL] [Abstract][Full Text] [Related]
20. Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors.
Lin HY; Han HW; Sun WX; Yang YS; Tang CY; Lu GH; Qi JL; Wang XM; Yang YH
Eur J Med Chem; 2018 Jan; 144():137-150. PubMed ID: 29268130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
